Exact Mass: 523.1788402

Exact Mass Matches: 523.1788402

Found 500 metabolites which its exact mass value is equals to given mass value 523.1788402, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

deacetylisoipecoside

C25H33NO11 (523.2053508)

Isoipecoside in which the acetyl group attaced to the nitrogen is replaced by hydrogen.

Deacetylipecoside

C25H33NO11 (523.2053508)

An isoquinoline alkaloid consisting of beta-D-glucose having a (2S,3R,4S)-3-ethenyl-4-{[(1R)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolinium-1-yl]methyl}-5-(methoxycarbonyl)-3,4-dihydro-2H-pyran-2-yl group attached at the anomeric centre.

3-(N-Maleimidopropionyl)biocytin

2-[3-(2,5-Dioxopyrrol-1-yl)propanoylamino]-6-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoylamino]hexanoic acid

C23H33N5O7S (523.2100588000001)

Deoxyribonucleic acid

[(5-amino-2-{[({[5-amino-2-(hydroxymethyl)oxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]methyl}oxolan-3-yl)oxy][(5-amino-3-hydroxyoxolan-2-yl)methoxy]phosphinic acid

C15H31N3O13P2 (523.1332056)

Hapten

3-(3-chloro-4-{14-cyclopropanecarbonyl-3,7-dimethyl-17-thia-2,4,5,8,14-pentaazatetracyclo[8.7.0.0^{2,6}.0^{11,16}]heptadeca-1(10),3,5,8,11(16)-pentaen-9-yl}phenyl)propanoic acid

C26H26ClN5O3S (523.1444796000001)

Penfluridol

1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]piperidin-4-ol

C28H27ClF5NO (523.1701222)

D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AG - Diphenylbutylpiperidine derivatives D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Penfluridol (R-16341) is a potent, long-acting, first-generation, oral diphenylbutylpiperidine antipsychotic agent by targeting D2-like dopamine receptor. Penfluridol effectively inhibits TNFα-induced NF-κB activation and alleviates the severity of arthritis and colitis in vivo. Penfluridol is a Ca2+-calmodulin inhibitor. Penfluridol induces apoptosis and autophagy. Penfluridol is used for chronic schizophrenia, acute psychosis, Tourette syndrome and autoimmune diseases. Penfluridol inhibites the growth of E. faecalis planktonic cells with the MIC of 7.81 μg/ml[1][2][3][4].

Pralnacasan

N-{4-[(2-ethoxy-5-oxooxolan-3-yl)carbamoyl]-6,10-dioxo-hexahydro-1H-pyridazino[1,2-a][1,2]diazepin-7-yl}isoquinoline-1-carboxamide

C26H29N5O7 (523.2066884000001)

4-(hydroxymethyl)phenyl 5-O-nicotinyl-beta-D-apiofuranosyl(1->2)-beta-D-glucopyranoside|cucurbitoside L

C24H29NO12 (523.1689674)

Cys Gly Asp Val Met

C19H33N5O8S2 (523.1770458000001)

N-(3-Maleimidopropionyl)biocytin

(2S)-6-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoic acid

C23H33N5O7S (523.2100588000001)

Gln Val Tyr Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]butanedioic acid

C23H33N5O9 (523.2278168)

N2-[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-1-oxopentyl]-L-lysine

C23H33N5O7S (523.2100588000001)

Trp-Nap-OH

(S)-2-(3-(2-(1H-indol-3-yl)ethoxy)-4-nitrobenzamido)-4-(naphthalen-2-yl)butanoic acid

C30H25N3O6 (523.174327)

Butyl 2-[[3-[[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)amino]carbonyl]-2-hydroxy-1-naphthyl]azo]benzoate

C29H25N5O5 (523.18556)

Sarecycline hydrochloride

C24H30ClN3O8 (523.172133)

C784 - Protein Synthesis Inhibitor > C1595 - Tetracycline Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic D003879 - Dermatologic Agents

COPPER(II) 3,5-DIISOPROPYLSALICYLATE HYDRATE

C26H36CuO7 (523.1756895999999)

Fmoc-Cys(Xan)-OH

C31H25NO5S (523.145336)

Idoxifene

C28H30INO (523.137204)

D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent

Pralnacasan

C26H29N5O7 (523.2066884000001)

C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic

Ibiglustat L-malate

C24H30FN3O7S (523.1788402)

C471 - Enzyme Inhibitor Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].

VX-740;Hmr 3480

C26H29N5O7 (523.2066884000001)

N-[4-[[5-[5-hydroxy-4-oxo-3-(phenylmethyl)-1,2-dihydroquinazolin-2-yl]-2-methoxyphenyl]methoxy]phenyl]acetamide

C31H29N3O5 (523.2107104)

JTE-607 free base

C25H31Cl2N3O5 (523.1640656)

PerMBP

C31H26NO5P (523.1548516)

4-[(2S,3R,4S,5R,6S)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]-8-ethyl-1-hydroxy-10,12-dimethoxynaphtho[1,2-c]isochromen-6-one

C29H33NO8 (523.2206058)

Hapten

C26H26ClN5O3S (523.1444796000001)

N-[3-[3-(1-piperidinylsulfonyl)anilino]-2-quinoxalinyl]benzenesulfonamide

C25H25N5O4S2 (523.1347890000001)

Asp-Phe-Asp-Gln

Ninerafaxstat (trihydrochloride)

C22H32Cl3N3O5 (523.1407432)

Ninerafaxstat (IMB-1018972) trihydrochloride is a novel mitotropic agent. Ninerafaxstat trihydrochloride increases myocardial metabolic efficiency by shifting substrate utilization towards glucose through reducing fatty acid oxidation (inhibiting 3-ketoacyl CoA thiolase). Ninerafaxstat trihydrochloride can be used for the research of cardiovascular diseases[1].

(e,2z)-2-{[(2s)-2-amino-3-(3,4-dihydroxyphenyl)-1-hydroxypropylidene]amino}-n-[(1e)-2-(3,4-dihydroxyphenyl)ethenyl]-3-(3,4,5-trihydroxyphenyl)prop-2-enimidic acid

C26H25N3O9 (523.159072)

(1s,14s,15r)-14-hydroxy-15-{[(2r,3s,4s,5r,6r)-6-(hydroxymethyl)-3,4,5-trimethoxyoxan-2-yl]oxy}-5,7-dioxa-12-azatetracyclo[10.5.2.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9-triene-13,17-dione

C25H33NO11 (523.2053508)

(4s,5r,6s)-5-ethenyl-4-{[(1s)-7-hydroxy-6-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylic acid

(4s,5r,6s)-5-ethenyl-4-{[(1s)-7-hydroxy-6-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylic acid

C25H33NO11 (523.2053508)

[9-(acetyloxy)-6-hydroxy-5a,8,11a-trimethyl-1-oxo-3-(pyridin-3-yl)-6,7,7a,9,10,11-hexahydro-2,5-dioxatetraphen-8-yl]methyl acetate

C29H33NO8 (523.2206058)

19-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]-11-hydroxy-3-(hydroxymethyl)-9-methyl-5-oxa-2-azapentacyclo[11.8.0.0²,⁶.0⁷,¹².0¹⁵,²⁰]henicosa-1(13),7,9,11,15,17,19-heptaene-4,14,21-trione

C27H25NO10 (523.147839)

C25H33NO11 (523.2053508)

(3s,6s)-19-{[(2s,4r,5r,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-11-hydroxy-3-(hydroxymethyl)-9-methyl-5-oxa-2-azapentacyclo[11.8.0.0²,⁶.0⁷,¹².0¹⁵,²⁰]henicosa-1(13),7,9,11,15,17,19-heptaene-4,14,21-trione

(3s,6s)-19-{[(2s,4r,5r,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-11-hydroxy-3-(hydroxymethyl)-9-methyl-5-oxa-2-azapentacyclo[11.8.0.0²,⁶.0⁷,¹².0¹⁵,²⁰]henicosa-1(13),7,9,11,15,17,19-heptaene-4,14,21-trione

C27H25NO10 (523.147839)

methyl 4-hydroxy-8-(hydroxymethyl)-2-methyl-1-oxo-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-3h-pyrrolo[3,2-e]indole-2-carboxylate

C26H25N3O9 (523.159072)

C22H29N5O10 (523.1914334)

2-amino-3-(3,4-dihydroxyphenyl)-n-(1-{[2-(3,4-dihydroxyphenyl)ethenyl]carbamoyl}-2-(3,4,5-trihydroxyphenyl)eth-1-en-1-yl)propanimidic acid

C26H25N3O9 (523.159072)

methyl (2r)-4-hydroxy-8-(hydroxymethyl)-2-methyl-1-oxo-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-3h-pyrrolo[3,2-e]indole-2-carboxylate

C26H25N3O9 (523.159072)

(4s,5r,6s)-5-ethenyl-4-{[(1r)-7-hydroxy-6-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylic acid

(4s,5r,6s)-5-ethenyl-4-{[(1r)-7-hydroxy-6-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylic acid

C25H33NO11 (523.2053508)

[(5as,6s,7ar,8r,9s,11ar)-9-(acetyloxy)-6-hydroxy-5a,8,11a-trimethyl-1-oxo-3-(pyridin-3-yl)-6,7,7a,9,10,11-hexahydro-2,5-dioxatetraphen-8-yl]methyl acetate

C29H33NO8 (523.2206058)

(5-{[4,5-dihydroxy-6-(hydroxymethyl)-2-[4-(hydroxymethyl)phenoxy]oxan-3-yl]oxy}-3,4-dihydroxyoxolan-3-yl)methyl pyridine-3-carboxylate

C24H29NO12 (523.1689674)